Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Non-Current Debt: 2011-2025

Historic Non-Current Debt for Ligand Pharmaceuticals (LGND) over the last 2 years, with Sep 2025 value amounting to $445.5 million.

  • Ligand Pharmaceuticals' Non-Current Debt was N/A to $445.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $445.5 million, marking a year-over-year change of. This contributed to the annual value of $205.4 million for FY2015, which is 4.83% up from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Non-Current Debt stood at $445.5 million, which was up 116.92% from $205.4 million recorded in Q4 2015.
  • In the past 5 years, Ligand Pharmaceuticals' Non-Current Debt ranged from a high of $445.5 million in Q3 2025 and a low of $445.5 million during Q3 2025.
  • For the 1-year period, Ligand Pharmaceuticals' Non-Current Debt averaged around $445.5 million, with its median value being $445.5 million (2025).